The dnrF gene, responsible for conversion of aklavinone to orhodomycinone via C-11 hydroxylation, was mapped in the daunorubicin (Dnr) gene cluster of Streptomyces peucetius ATCC 29050, close to drrAB, one of the anthracyclineresistance genes. The dnrF gene was sequenced and should encode a protein of 489 amino acids with a molecular mass of 52 kDa. The deduced DnrF protein shows significant similarities with bacterial FAD-and NADPH-dependent hydroxylases either required to introduce hydroxyl groups into polycyclic aromatic polyketide antibiotics or involved in catabolism of aromatic compounds. Heterologous expression of dnrF in Streptomyces liwidans TK23 and in Escherichia coli demonstrated that the gene encodes a NADPHdependent hydroxylase catalysing the hydroxylation of aklavinone to yield Erhodomycinone. The enzyme is inactive on anthracyclines glycosylated at position C-7 and its activity decreases to a different extent with other substrate modifications, indicating that DnrF has a significant substrate specificity.
INTRODUCTION
Keywords : aklavinone, hydroxylase, dnrF gene, anthracycline, Streptomyces peacetias Daunorubicin (Dnr) and especially its C-14 hydroxylated derivative doxorubicin (Dxr) are important antitumour agents used for the treatment of many different cancers (Arcamone, 1981) . Unfortunately, besides their antineoplastic activity, they have long-term undesirable effects such as cardiotoxicity (Myers et al., 1988) . For this reason, studies are being done to develop new Dnr derivatives or new anthracyclines showing an increased antitumour spectrum and, at the same time, reduced cardiotoxicity (Cassinelli e t al., 1978 ; Crespi-Perellino e t al., 1982; White & Stroshane, 1984) . New possibilities for structural changes, resulting from recent progress in the molecular genetics of Streptomyes, have opened a promising line in the development of hybrid antibiotics (Floss & Strohl, 1991 ; Hopwood e t al., 1985b; Hutchinson, 1992; Strohl e t al., 1989) . This approach requires the understanding of the anthracycline Abbreviations: Dnr, daunorubicin; Dxr, doxorubicin; GST, glutathione Stransferase.
The GenBank accession number of the sequence reported in this paper is U18082.
biosynthetic pathway as well as the function of the single genes and enzymes involved.
Stutzman-Engwall & Hutchinson (1989) and Otten et al. (1990) have cloned, in a series of cosmids, the entire Dnr biosynthesis gene cluster of Streptomyes petleetius ATCC 29050. Single genes of the cluster have been isolated recently, sequenced and expressed in heterologous systems to enable partial characterization of Dnr biosynthesis enzymes (Madduri e t al., 1993) .
Previously we reported the isolation of a Dxr-Dnr resistance gene contained in a 5.7 kb fragment (riel) from S. petlcetitls subsp. caesitls mutant 7600 derived from ATCC 27952 (Colombo e t al., 1992) . riel belongs to the Dnr cluster described by Stutzman-Engwall & Hutchinson (1 989) and the identified resistance gene corresponds to the drrAB gene (Guilfoile & Hutchinson, 1991) . We also presented preliminary evidence that in the same fragment, close to drrAB, is a gene responsible for conversion of aklavinone to e-rhodomycinone via hydroxylation at C-11. This finding is consistent with the observation, made by Guilfoile & Hutchinson (1991) On: Thu, 03 Jan 2019 11:54:21 S. F I L I P P I N I a n d O T H E R S opposite direction. T h e ORF was only partially sequenced but comparison of the deduced first 79 amino acids revealed a significant similarity with FAD-and NADPHdependent bacterial hydroxylases (Blanco e t a/., 1993 (Grein et al., 1963) , 7600, 7800 and 9700 (Colombo et al., 1992) and the plasmids pWHM3 (Vara et al., 1989) , pWHM603 (Guilfoile & Hutchinson, 1991) and ricl (Colombo et al., 1992) are described elsewhere. The ermE* promoter (Gramajo et al., 1991) was isolated from pIJ4070 kindly provided by M. J. Bibb (unpublished results). pUC19, M13mp18 and M13mp19 were purchased from New England Biolabs. pT7-7 was from USB and pGEX-2T was from Pharmacia Biotech. Plasmid pGP1-2 was provided by C. R. Hutchinson. The Escherichia coli strains used were JM109 (Yanisch-Perron et al., 1985) , DH5a (BRL) and DH1 (Hanahan, 1983) . Plasmids pFI 15 and pLA-4 contain the dnrF gene, obtained by PCR amplification as detailed later, cloned into the EcoRI site of pT7-7 and pGEX-2T vectors, respectively. Plasmid pFI 14 contains a region of 2.2 kb, obtained by partial digestion of pWHM603 with BamHI, cloned into the BamHI site of the pWHM3 vector (see Fig. 1 ). The 1.7 kb XbaI fragment containing the dnrF gene from pFI 15 was cloned into the XbaI site of pIJ4070 downstream of the ermE* promoter, obtaining plasmid pFI 16. pFI 16 was double digested with Sac1 and Hind111 and the 2 kb fragment, corresponding to the ermE*-dnrF hybrid gene, was inserted into pWHM3 digested with the same enzymes to obtain pFI 20. Chemicals. Thiostrepton was obtained from Behring Diagnostic. Aklavinone, 1 0-decarbomethoxy-aklavinone, 11 -deoxycarminomycinone, 1 1 -deoxydaunomycinone, 1 1 -deoxy-4-demethyladriamycinone, 1 1 -deoxycarminomycin, 1 1 -deox ydaunom y cin and 1 1 -deoxy-4-demethyldaunomycin were prepared in the laboratories of Oncology Area Pharmacia Farmitalia-Carlo Erba. Restriction enzymes and other molecular biology materials were purchased from standard commercial sources. All other chemicals and biochemicals, unless specified, were obtained from Sigma. DNA sequence analysis. The 1.6 kb and 0.6 kb BamHI fragments from pWHM603 (see Fig. 1 ) containing the dnrF gene were subcloned in pUC19, M13mp18 and M13mp19 vectors. Plasmids for sequencing reactions were prepared using Qiagen columns. Single-stranded DNA templates were isolated from E. coli JM109 cultures according to the method of Sambrook et al. (1989) . The templates were sequenced by the chain-termination method with Sequenase 2.0 (USB) using [35S]dCTPaS following the manufacturer's instructions and 7-deaza-dGTP or dITP to reduce the number of sequencing artefacts. Synthetic oligonucleotide primers made by a DNA synthesizer model 391 (Applied Biosystems) were used to obtain the nucleotide sequence of both strands. FASTA and TFASTA searches were performed with the GenBank databank. Expression of the DnrF protein in E. coli and the bioconversion assay. Plasmid pFI 14 was used as template for the amplification of the dnrF gene. PCR was carried out with the GeneAmp DNA amplification kit (Perkin Elmer Cetus) according to the instructions of the manufacturer except for the addition of glycerol (10 %, v/v, final concentration) and formamide (5%, v/v). The primers used in the amplification reaction were : 5'-dnrF (5' AGGAATTCAGGTG GCCTTGACGAAGCCGGATGTC 3') containing the putative G T G translation start site (underlined) and 3'-dnrF (5' AGGAATTCGGGACGCTCCGGTCAGCGGGCCAGC 3') 128 nt downstream of the ORF stop codon. Both primers have an EcoRI site at their 5' end (bold). Before addition of Tag polymerase and dNTPs, the reaction mixture was heated at 95 "C for 7 min, overlaid with mineral oil and then incubated for 3 min at 70 "C. The temperature program was as follows: 25 cycles of 1 min at 94 O C , 1 min at 65 O C and 2 min at 72 "C. The PCR product, with a size of 1-6 kb, was purified from an agarose gel with a QIAquick gel extraction kit (Qiagen), cloned into TA vector (TA cloning kit ; Invitrogen) and analysed by restriction enzyme digestion. The 1.6 kb insert, corresponding to the dnrF gene, was cut out from the TA vector by EcoRI digestion and cloned into the EcoRI site of pGEX-2T or pT7-7. To induce expression of the GST-DnrF fusion protein, mid-log phase DH5a(pLA-4) cultures (OD,,, = 0-6) were grown in 2 mM isopropyl-B-D-thiogalactoside (IPTG ; Boehringer Mannheim) for an additional 3 h at 37 "C. The fusion protein was extracted and purified using glutathione agarose (G-4510, Sigma) as described by Smith & Johnson (1988) .
The expression in E. coli of the unfused DnrF protein was achieved by the pT7-7 system. E. coli DH1 cells were first transformed with the pGP1-2 plasmid (Tabor & Richardson, 1985) bearing the kanamycin-resistance gene. pGPl-2 enabled the expression of the T7 RNA polymerase under the control of the 1 PL promoter. Kanamycin-resistant cells were transformed with pFI 15 bearing the ampicillin-resistance gene and the entire dnrF gene under the control of the 410 promoter specifically recognized by the T7 RNA polymerase (Tabor & Richardson, 1985) . Double transformants were grown at 30 OC. For the induction of dnrF, E. coli DHl(pGP1-2/pFI 15) cells were grown in 2 x Y T medium (Sambrook et al., 1989 ) (made with 80 pg ml-' of both kanamycin and ampicillin). At OD,,, = 3.0 the temperature was raised to 42 "C for 30 min, then the cells were grown for 120 min further at 30 "C.
For the bioconversion assay anthracyclines dissolved in DMSO at 50 pg ml-' and NADPH (5 mM final concentration) were added to a DHl(pGPl-2/pFI 15) induced culture and cells were grown for a further 60 min at 30 "C. The cultures were extracted and analysed by HPLC. Enzymic assay for the DnrF protein with E. co/i crude extracts.
Induced E. coli DHl(pGP1-2/pFI 15) cells were harvested by centrifugation at 3000 g at 4 "C, resuspended in 4 vols cold lysis buffer (25 mM Tris/HCl pH 8-0,150 mM NaC1,2 mM EDTA), disrupted by sonication and centrifuged at 15 000 g. The assay was performed by shaking the supernatant at 37 "C for 60 min in 100 mM potassium phosphate buffer (pH 7.7) containing NADPH (5 mM) and substrates (at the indicated concentrations) dissolved in DMSO. Further reaction was blocked by adding an equal volume of acetonitrile/methanol (1 : 1, v/v). After vortexing and centrifugation, the supernatant was filtered and analysed by reverse-phase HPLC. Enzymic assay for the DnrF protein with 5. lividans crude extracts. S. lividans (pFI 20) was grown in YEME medium (Hopwood e t al., 1985a) for 76 h, harvested by centrifugation, washed in PBS, resuspended in 4 vols lysis buffer and disrupted by sonication. After centrifugation at 15 000 g the supernatant was used as a crude enzyme preparation.
HPLC analysis. Acetonitrile/methanol (1 : 1, v/v) was used to extract the metabolites, The extracts were filtered by a Millex-GV 0.45 pm filter (Millipore) before HPLC analysis. The metabolites were identified by HPLC with a reverse-phase Hypersil ODs-microbore column (Shandon). A linear gradient of 23-67 % acetonitrile buffered at pH 2.5 with 12.5 mM sodium monobasic phosphate was applied for 52 min at a flow rate of 0.125 ml min-l. The elution profile was monitored with a Hewlett-Packard diode array detector at 488, 424 or 254 nm. Streptomyces transformation and bioconversion experiments. Protoplasts were produced from S. lividans TK23 grown in YEME medium supplemented with 0.5% glycine at 28 O C as described by Hopwood et al. (1985a) and regenerated on R2YE agar. S. lividans transformants were selected and maintained on thiostrepton at 50 pg ml-'.
S. lividans TK23(pFI 14) or S. lividans TK23(pFI 20) was grown
for 48 h in YEME medium at 30 "C. One millilitre of the culture was used to inoculate 25 ml fermentation medium described by McGuire et al. (1979) . Anthracyclines were added to 68 h cultures and, after 24 h, 650 mg oxalic acid was added. Cultures were incubated at 50 OC for 45 min, then the crude extracts were prepared and analysed by HPLC.
Preparation of antisera to the GST-DnrF fusion protein.
Antibodies against the purified recombinant protein were produced in 6 week old Balb/c female mice according to the following protocol : the first intraperitoneal shot contained 50 pg purified recombinant protein in 50 pl sterile PBS plus 50 pl complete Freund adjuvant. Four more injections, at 2 week intervals, were done with the same amount of antigen but without adjuvant. In Western blot analysis the serum was used at a 1 : 1000 dilution. Protein analysis. SDS-PAGE and Western blot analysis were performed as previously described (Buvoli et al., 1990) . Mouse anti-GST-DnrF antibodies were used at a 1 : 1000 dilution and revealed by alkaline-phosphatase-conjugated anti-mouse IgG (Promega).
RESULTS
Cloning and sequencing of the aklavinone 11-hydroxylase gene W e previously reported the isolation and characterization of ricl, a 5.7 kb DNA fragment from the S. pencetins 7600 mutant, which contains the Dxr-Dnr resistance gene (drrAB) . Bioconversion experiments with S. lividans TK23 (ricl) suggested the presence, close to drrAB, of the dnrF gene, which converts aklavinone (a yellow compound) t o c-rhodomycinone (red) via 11 -hydroxylation (Colombo et al., 1772) .
W e have now mapped, by means of the same bioconversion assay, the dnrF gene within pWHM603 (Guilfoile & Hutchinson, 1971) , which contains part of the D n r cluster from S.pezrcetitls ATCC 29050 (Fig. 1) . T h e region conferring the ability t o S. lividans TK23 t o convert the added aklavinone to c-rhodomycinone (80 % conversion) is located in a 2.2 k b fragment (plasmid pFI 14) (Fig. 1) .
T h e pFI 14 insert was sequenced and, as shown in Fig. 2 , the first 118 n t correspond t o the 5' end of the drrAB gene (non-coding strand) (Guilfoile & Hutchinson, 1771) . T h e ORF for the dnrF gene was identified on the basis of previously reported considerations (Bibb e t al., 1784) about the distribution of G + C content across codons in Streptomyces genes. T h u s a region spanning from position 352 t o 1822 contains the dnrF gene (Fig. 2) , beginning with a putative GTG translation start codon and ending with a TGA stop codon. A plausible ribosome-binding site (GGAGG) (Strohl, 1772 ) is located 6 n t upstream of the GTG codon. T h e first 237 n t of the ORF were previously sequenced by Guilfoile & Hutchinson (1 771 C GAT CCC GTA GAC GAG ACC CGC CGG QC GTT GAG GTC CAC CCC GTC CAC CGC CCT CGT CCC Gll GTA GAC CTT GAC GAG ACC GGA CGT TTC GAT GGC CCG TGT CGG CTC CGT Gll
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A M S P P P P A N * resemblance to two groups of hydroxylase enzymes ( Fig.  3) : those catalysing the introduction of hydroxyl groups into polycyclic aromatic polyketide antibiotics (Blanco e t al., 1993; Decker e t al., 1993) and those involved in catabolism of aromatic compounds in different organisms (Blanco et al,, 1993; Kalin e t al., 1992; Nurk e t al., 1991 ; Perkins etal., 1990; Weijer etal., 1982) . No similarity with P-450 cytochromes (Andersen e t al., 1993; Stassi e t al,, 1993; Weber e t al., 1991) involved in the hydroxylation of erythromycin, or with act V A gene products (Caballero e t al., 1991) , responsible for hydroxylation of the ring structures in actinorhodin biosynthesis, was found. As shown in Fig. 3 , the DnrF enzyme contains two motifs that are common to a number of FAD-and NADPHdependent enzymes. The first motif, located at the Nterminus of the protein (amino acids 3-47), is the so called Po$ fold and is involved in binding of the ADP moiety of FAD (Wierenga et a/., 1986) . The second motif seems to be important in binding the ribityl chain of the flavin moiety of FAD (Eggink e t al., 1990; Russel & Model, 1988) . These similarities further support the conclusion that the dnrF gene encodes for the aklavinone 11-h ydroxylase.
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Expression of the dnrF gene in Streptomyces and in E. coli
We stated above that, upon transformation with pFI 14, S. 1i~idan.r acquired the ability to bioconvert aklavinone to e-rhodomycinone. Incubations for 1 h gave 1 1-hydroxylation of 10% of the aklavinone (50 pg ml-l) added to the medium. Complete conversion was seen after 6 h. Since this could be due to low levels of gene expression, we cloned the dnrF gene (1605 nt) into the pWHM3 vector under the control of the strong ermE* promoter (pFI 20 plasmid; see Methods). S. lividans(pF1 20)
converted 100% of aklavinone (50 pg ml-') to Erhodomycinone in l h incubations. Moreover, this transformant also catalysed the hydroxylation of compounds biochemically derived from a klavinone (see Table 1 and Fig. 4) , but it had no activity with molecules other than anthracyclines (Table 1) .
For an initial biochemical characterization we expressed the dnrF gene in E. coli as a fusion with GST. To this aim the dnrF gene was PCR-amplified and cloned into the EcoRI site of the pGEX-2T vector (see Methods). The GST-DnrF fusion, purified on a glutathione agarose column, was assayed for its ability to convert aklavinone to e-rhodomycinone and used as antigen to raise polyclonal antibodies in a mouse. Since the fusion protein did not show any hydroxylase activity (data not shown), we cloned the dnrF gene into the pT7-7 vector that allowed the expression of an unfused DnrF protein.
Interestingly, upon transformation with this construct (pFI 15), E. coli was able to bioconvert aklavinone to Erhodomycinone (Table l) . Furthermore, the cell extract prepared from E. coli(pF1 15) (see Methods) catalysed the aklavinone 1 1 -hydroxylation in a NADPH-dependent reaction, as determined by HPLC analysis (Fig. 5) . Both E. coli(pF1 15) cells and crude extracts were active on substrates other than aklavinone, and showed the same specificity observed with S. lividans(pF1 20) cells and extracts (Table 1) .
To confirm the expression of the DnrF protein in heterologous systems we carried out Western blot experiments using the antibodies raised to the GST-DnrF fusion. As shown in Fig. 6 
DISCUSSION
In this paper we report the sequencing and expression of the dnrF gene from S. pezlcetitls ATCC 29050. The gene belongs to the Dxr-Dnr biosynthetic gene cluster and, as previously suggested (Colombo et al., 1992) , it is closely associated with the Dxr-Dnr resistance gene drrAB. The dnrF gene encodes an enzyme of 489 amino acids that catalyses the conversion of aklavinone to E-rhodomycinone via 1 1 -hydroxylation. Accordingly, the analysis of the deduced DnrF protein sequence revealed the presence of two motifs common to a number of FAD-and NADPH-dependent hydroxylases involved in catabolism of aromatic compounds. As shown in Fig. 3 , both regions are formed by alternating divergent and conserved sequences. In particular, the more C-terminal motif seems to be formed by three conserved regions separated by amino acid stretches containing Gly and Pro, two residues very often associated with protein bending. The first conserved box is the only one where Cys or His can be found. It is intriguing to observe that DnrF is the only protein among those shown that lacks these residues. We think that these differences could reflect enzymic specificity and, at the same time, can be used as a measure of the relatedness of different members of this protein family.
For preliminary biochemical characterization we expressed the dnrF gene in both 5'. lividans and E. coli cells.
In vitro conversion assays carried out with crude extracts demonstrated that the 1 1 -hydroxylation reaction is NADPH-dependent. DnrF has a significant substrate specificity, since it is completely inactive on molecules other than anthracyclines (see Table 1 ).
Aklavinone, the natural substrate, is a key intermediate in the biosynthesis of Dxr and Dnr and requires several successive chemical modifications such as hydroxylation, glycosylation, oxidation and methylation. DnrF catalyses the first among these modifications, i.e. 1 1-hydroxylation of aklavinone (yellow) to E-rhodomycinone (red). The fact that DnrF acts early in the metabolic pathway of Dnr biosynthesis does not mean that 1 1-hydroxylation is required for all the successive inodifications to take place. For instance, the dnrF 7800 mutant is able to produce 1 1 -deoxydaunorubicin (yellow) and 1 1 -deoxydoxorubicin (yellow). These results support the alternative hypothesis that the temporal order is simply linked to the substrate specificity of the enzyme because DnrF utilizes the 11- deoxy compounds, downstream of aklavinone in the biosynthetic pathway, much less efficiently than aklavinone. In particular, the enzyme is completely inactive on the C-7 glycosylated intermediates (compare the 1 1 -deoxycarminomycin to 1 1 -deoxycarminomycinone conversion in Table 1 ). Our data also indicate that modifications of the aklavinone molecule can influence the efficiency of the hydroxylation carried out by DnrF. While molecules modified in positions C-10 and C-13 are hydroxylated as efficiently as aklavinone (see 11-deoxycarminomycinone conversion, Table 1 and Fig. 4) , molecules 14-hydroxylated or 4-methylated are very poor substrates (see 1 1 -deoxy-4-demethyladriamycinone and 11-deoxydaunomycinone conversion, Table 1 and Fig. 4) . The hydroxyl group in position 11 of anthracyclines seems to have a primary biological role, since all the red compounds (1 1 -hydroxylated) are more toxic for Streptumjces and more cytotoxic for animals than the yellow 11-deoxy analogues (Oki, 1988) .
The drrAB gene is one, and probably the most important, of the Strepturnyes genes conferring resistance to Dxr and Dnr (Colombo e t al., 1992; Guilfoile & Hutchinson, 1991) . We have previously shown that the drrAB mRNA appears in parallel with Dnr production, suggesting that drrAB gene expression is regulated at the transcriptional level (Colombo e t al., 1992) . As suggested previously (Guilfoile & Hutchinson, 1991) (Beck & Warren, 1988) . One indication supporting this idea derives from the dnrF 7800 mutant that produces 1 1-deoxydaunorubicin a n d 11-deoxydoxorubicin. This mutant fails to express the drrAB gene and is sensitive to D x r and D n r . It is reasonable to think that the drrAB gene is primarily involved in conferring resistance to 1 1 -hydroxylated anthracyclines and therefore is absolutely required after the activation of the dnrF gene.
Altogether these considerations point to the drrA&dnrF gene system as a possible target for a major control point in the anthracycline biosynthetic pathway, a hypothesis that deserves further analysis.
